Krystal Biotech Inc Stock News

Krystal Biotech (NASDAQ:KRYS) had its target price raised by The Goldman Sachs Group from $85.00 to $125.00 in a research note issued to investors on Tuesday, Price Targets.com reports. They currently have a buy rating on the stock. Other equities research analysts have also recently issued reports about the stock. HC Wainwright upped their price []

Krystal Biotech, Inc. (NASDAQ:KRYS)s stock price gapped up prior to trading on Tuesday after The Goldman Sachs Group raised their price target on the stock from $85.00 to $125.00. The stock had previously closed at $88.24, but opened at $98.00. The Goldman Sachs Group currently has a buy rating on the stock. Krystal Biotech shares []

PITTSBURGH, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (NASDAQ: KRYS) (the “Company”), the leader in redosable gene therapies for rare diseases, today announced that it has priced t

PITTSBURGH, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (NASDAQ: KRYS) (the Company), the leader in redosable gene therapies for rare diseases, today announced that it has priced the previously announced underwritten public offering of 2,666,667 shares of its common stock, at a public offering price of $75.00 per share. The Company and certain selling stockholders granted the underwriters a 30-day option to purchase up to an additional 400,000 shares of the Companys common stock offered in the public offering. The gross proceeds to the Company from this offering are expected to be approximately $200 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by the Company. All of the shares to be sold in the proposed offering will be sold by the Company other than up to 200,000 shares of the Companys common stock that may be sold by the selling stockholders in connection with the exercise of the underwriters option to purchase additional shares.

Companies in the news are: KRYS, ADGI, NRXP, HTZ

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Cumberland Gets FDA Approval For IV-Delivered Ibuprofen For Use In Pre-Operative Administration Cumber

Krystal Biotech Inc. (NASDAQ:KRYS) traded at $88.24 at close of the session on Monday, 11/29/21, made an upward move of 121.65% on its previous days price. Looking at the stock we see that its previous close was $39.81 and the beta (5Y monthly) reads 1.11 with the days price range being $83.76 $102.99. In Krystal Biotech Inc.s Stock Price Plummeted Recently, But There Might Be Trouble Ahead Read More »

Positive results were obtained from the phase 3 GEM-3 study using VYJUVEK for the treatment of patients with dystrophic Epidermolysis Bullosa. STAR-D technology platform is highly efficient in using a

PITTSBURGH, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (NASDAQ: KRYS) (the “Company”), the leader in redosable gene therapies for rare diseases, today announced that it has commence

PITTSBURGH, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (NASDAQ: KRYS) (the Company), the leader in redosable gene therapies for rare diseases, today announced that it has commenced a $200 million underwritten public offering of its common stock. The Company and certain selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional $30 million of the shares of the Companys common stock offered in the public offering. The offering is subject to market and other conditions, and there can be no assurances as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All of the shares to be sold in the proposed offering will be sold by the Company other than up to 200,000 shares of the Companys common stock that may be sold by the selling stockholders in connection with the exercise of the underwriters option to purchase additional shares.

Shares of Krystal Biotech Inc (NASDAQ: KRYS) more than doubled on Monday after the gene therapy company said its pivotal GEM-3 trial for VYJUVEK reported positive topline results. GEM-3 trial met its

Shares of Krystal Biotech Inc (NASDAQ: KRYS) more than doubled on Monday after the gene therapy company said its pivotal GEM-3 trial for VYJUVEK reported positive topline results. GEM-3 trial met its primary and secondary endpoint According to Krystal Biotech, the study involving its topical treatment for Dystrophic Epidermolysis Bullosa (Dystrophic EB) achieved the primary [] The post Krystal Biotech shares are up 140% on Monday: heres the catalyst appeared first on Invezz.

The stock price of Krystal Biotech Inc (NASDAQ: KRYS) increased by 121.65% today. This is why it happened.